SCR6106
/ Simcere
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 13, 2021
[VIRTUAL] SCR6106, an oral and brain penetrant SERD demonstrated anti-tumor activities in vitro and in vivo
(AACR 2021)
- "Fulvestrant, a selective estrogen receptor degrader (SERD) is approved to treat HR+ metastatic breast cancer in patients with disease progression after endocrine therapy. In conclusion, SCR6106 is a novel, potent and oral SERD, which demonstrated anti-tumor activities in vitro and in vivo. It showed high potential ability to cross the blood-brain barrier, and could be used to treat HR+ patients with brain metastasis."
Preclinical • Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor • ER
1 to 1
Of
1
Go to page
1